A new study validating OptiScan’s endomicroscopic technology has this week been published in Nature Biomedical Engineering, one of the world’s leading medical research journals.
The study, led by Memorial Sloan Kettering Cancer Centre, found that OptiScan’s ViewnVivo “has the potential to be used for intraoperative, PARPi-FL-based in vivo imaging without tissue excision”.
OptiScan’s technology enables real-time, 3D, in vivo imaging of human tissue at the cellular level. It provides instant virtual biopsies for cancer screening, diagnoses, and treatment.
For more on the study, visit: https://www.nature.com/articles/s41551-020-0526-9